Public Health

Insights on disease prevention and control, health promotion and education, environmental health and health equity and social justice.

Assessing strategies for mitigating infectious diseases

Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.

Watch the webinar: An introduction to infectious disease modelling

In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.

Read the whitepaper

Antimicrobial resistance

The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.

Watch the webinar: Antimicrobial resistance - How clinical research can combat an ensuing global crisis

In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.

Read the whitepaper

Fortifying vaccines: Preparation and prevention against future infectious disease epidemics

This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.

Read the whitepaper

A multifaceted risk factor:

Addressing obesity's impact across the disease spectrum

2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.

Read the whitepaper

ICON survey report:

Trends and challenges in obesity research and clinical trials

This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future. 

Read the survey report

The evolution of HIV treatments

HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.

Read the whitepaper

Pandemic respiratory vaccine clinical trials: A departure from business as usual

Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.

Read the whitepaper

COVID-19 vaccines: Post-authorisation safety surveillance

This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts.

Read the whitepaper

Diversity and inclusion in clinical trials

Examining how the field of clinical research currently approaches diversity and inclusion gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.

Learn more

Science-led. Mission driven.

At ICON, our dedicated Government and Public Health Solutions team have been advancing the future of global health for over 30 years. Discover more about their work with US Government and NGOs.

Read more